Press "esc" to clear
Go to Advanced Search

Showing results

110 of 2246
Eisfeld_picture.jpg

Article ID: 698814

Research Grant to Study Common Resistance to Papillary Thyroid Cancer Treatment Is Awarded to Ann-Kathrin Eisfeld, MD, by the American Thyroid Association

American Thyroid Association

The American Thyroid Association has awarded a 2018 Research Grant to Ann-Kathrin Eisfeld, MD, Clinical Fellow in Internal Medicine at Ohio State University. The topic of Dr. Eisfeld’s project is “Novel NRAS isoform mediates BRAF-inhibitor resistance in papillary thyroid cancer—thinking outside the box to overcome ‘inevitable’ treatment failure.” Papillary thyroid cancer (PTC) is one of the 10 most common malignancies in the United States, with almost 60,000 new people diagnosed each year. While almost all patients initially respond well to the current standard treatment with radioactive iodine, almost half of them will eventually develop resistance. Therapies that can provide additional treatment options for those patients are greatly needed.

Released:
14-Aug-2018 8:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
5-photocintiacitterio.jpg

Article ID: 698721

Research Grant Focused on Identifying T3-Forming Sites in Thyroglobulin Is Awarded to Cintia Eliana Citterio, PhD, by the American Thyroid Association

American Thyroid Association

The American Thyroid Association has awarded a 2018 Research Grant to Cintia Eliana Citterio, PhD, Assistant Professor of Genetics and Molecular Biology at the Instituto de Inmunología, Genética y Metabolismo (INIGEM), Universidad de Buenos Aires (UBA) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Dr. Citterio’s project is called “De novo triiodothyronine (T3) formation in T3 toxicosis of Graves’ Disease.” The project focuses on identifying T3-forming sites in thyroglobulin (TG, the protein from which thyroid hormone is made) that are responsible for excess T3 production in patients with autoimmune hyperthyroidism or Graves’ Disease (GD).

Released:
14-Aug-2018 8:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
MilesWaynePhD4216.jpg

Article ID: 698821

Research Grant to Determine the Genes Responsible for Survival and Growth of Medullary Thyroid Cancer Is Awarded to Wayne Miles, PhD, by the American Thyroid Association

American Thyroid Association

The American Thyroid Association has awarded a 2018 Research Grant to Wayne Miles, PhD, Assistant Professor of Molecular Genetics at the Ohio State University. Dr. Miles’s research project is entitled “Proteomic-led discovery of essential genes in Medullary Thyroid Cancer.” Medullary thyroid cancer (MTC) is caused by the malignant growth of C-cells. Although MTC represents only a small fraction (2¬4%) of all thyroid cancer cases and overall survival rates from MTC are good, patients diagnosed with advanced disease have poor five-year survival rates (28%). The genetic aberrations of the cancer result in C-cells receiving a continuous signal to grow and proliferate. To sustain their elevated growth rates, MTC cells adapt their genome (DNA), transcriptome (RNA), and proteome (the entire set of proteins expressed by a cell, tissue, or organism).

Released:
14-Aug-2018 8:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Tardi_Nick-LR.jpg

Article ID: 698826

Research Grant to Identify the Source and Mechanism of Thyroid and Kidney Comorbidity Is Awarded to Nicholas Tardi, PhD, by the American Thyroid Association

American Thyroid Association

The American Thyroid Association has awarded a 2018 Research Grant to Nicholas J. Tardi, PhD, Instructor in Internal Medicine at Rush University Medical Center in Chicago. Dr. Tardi’s project is titled “Deiodinase 3: A Thyroid Hormone-Associated Renoprotective Protein.” The long-term goal of this project is to identify the source and mechanism of kidney and thyroid comorbidity. Thyroid hormone (TH) is a circulating, lipid-soluble molecule that plays an important physiological and developmental role in nearly all cells. Accordingly, precise control of TH activity is crucial to maintain metabolic homeostasis in several tissues.

Released:
14-Aug-2018 8:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
MilesMiller_Portrait.jpeg

Article ID: 698825

Research Grant to Determine How Specific Drugs Work or Fail in Anaplastic Thyroid Cancer Is Awarded to Miles Miller, PhD, by the American Thyroid Association

American Thyroid Association

The American Thyroid Association has awarded a 2018 Research Grant to Miles Miller, PhD, principal investigator at the Massachusetts General Hospital Center for Systems Biology and Assistant Professor of Radiology at Harvard Medical School. Dr. Miller’s research project is titled “Co-opting tumor-associated macrophages in anaplastic thyroid cancer to enhance immune-checkpoint blockade response.” Treatment of advanced metastatic cancer has seen a revolution over the last several years, as new therapeutic strategies have become successful at harnessing the power of the immune system to durably attack malignant and mutated cancer cells. Immune-checkpoint blockade therapies targeting programmed-death 1 (PD1) signaling on T-cells have been successful in the treatment of solid cancers, including heavily mutated melanomas and lung cancers. Unfortunately, these treatments only work in a fraction of patients, and resistance is often associated with the presence of a type of tumor-promoting imm

Released:
13-Aug-2018 11:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
behringerphoto.jpg

Article ID: 698829

Research Grant to Study the Action of T-Regulatory Cells in Thyroid-Antibody-Positive Pregnant Women Awarded to Stephanie Behringer-Massera, MD, by the American Thyroid Association

American Thyroid Association

The American Thyroid Association has awarded a 2018 Research Grant to Stephanie Behringer-Massera, MD, Clinical Fellow at the Icahn School of Medicine at Mount Sinai. Dr. Behringer-Massera’s project is titled “T regulatory cells in thyroid-antibody-positive pregnant women.” A fetus, which shares half its genetic material with the father, is considered a foreign body in the mother’s womb. The only way that it can implant in the uterus without being rejected is if the mother’s immune system is suppressed, which happens through T-regulatory-cell action. The more T regulatory cells (Tregs) are released, the more the immune system is suppressed and the more likely the pregnancy can successfully be brought to term. In women with autoimmune thyroid disease, this process is disrupted. These women are found to have an abnormal Treg response to pregnancy and have Treg levels as low as women who are not pregnant. They are more likely to have miscarriages in the first trimester.

Released:
13-Aug-2018 11:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
SRCs_HallB.jpg
  • Embargo expired:
    13-Aug-2018 11:00 AM EDT

Article ID: 698832

Protons Get Zippier in Neutron-Rich Nuclei

Thomas Jefferson National Accelerator Facility

A new study carried out at the Department of Energy's Thomas Jefferson National Accelerator Facility has confirmed that increasing the number of neutrons as compared to protons in the atom’s nucleus also increases the average momentum of its protons. The nuclear physics result, which has implications for the dynamics of neutron stars, has been published in the journal Nature.

Released:
10-Aug-2018 12:30 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
91-freeman-teaching.jpg

Article ID: 698865

Academy of Management Honors UVA Darden Professor Ed Freeman With Lifetime Achievement Award

University of Virginia Darden School of Business

The Academy of Management (AOM) awarded University of Virginia Darden School of Business Professor Ed Freeman the 2018 Award for Distinguished Scholarly Contributions to Management at its annual meeting in Chicago on 12 August.

Released:
13-Aug-2018 10:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Education

Picture_BFrett002.jpg

Article ID: 698816

Research Grant for Study of Resistance to Precision Medication for Medullary Thyroid Cancer Is Awarded to Brendan Frett, PhD, by the American Thyroid Association

American Thyroid Association

The American Thyroid Association has awarded a 2018 Research Grant to Brendan Frett, PhD, Assistant Professor in the College of Pharmacy at the University of Arkansas for Medical Sciences. The title of Dr. Frett’s project is “Dual Inhibition of RET and Aurora B to Study the Simultaneous Regulation of Multiple Oncogene Pathways in Medullary Thyroid Cancer.” Since its inception in 1971, the War on Cancer has resulted in significant treatment breakthroughs. One of the most important was the discovery of cancer-promoting oncogenes (genes with the potential to cause cancer). Researchers theorized that oncogenes could be strategically targeted while sparing normal cells, which sparked the era of precision medicine for oncology. Early medicine discoveries were quickly followed by the realization that secondary mutations in cancers often resulted in resistance to the drugs and relapse of the disease. This was solved by generating inhibitors that achieved activity on multiple forms of the onc

Released:
13-Aug-2018 10:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 698860

2018 AAPS Election Results Announced

American Association of Pharmaceutical Scientists (AAPS)

Joseph W. Polli, Ph.D., FAAPS, GlaxoSmithKline has been elected to serve as president-elect of the American Association of Pharmaceutical Scientists (AAPS), a professional member-based organization of approximately 9,000 located in Arlington, VA.

Released:
13-Aug-2018 9:30 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Showing results

110 of 2246





Chat now!